Patent application number | Description | Published |
20090246776 | Modulators of scarb-1 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the SCARB-1 receptor, and the use of modulators of the expression or activity of this receptor for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 10-01-2009 |
20100021892 | Modulators of SC4MOL for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of sterol-C4-methyl oxidase (SC4MOL), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 01-28-2010 |
20100021893 | Modulators of lanosterol synthetase for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of lanosterol synthetase (LSS), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 01-28-2010 |
20100028879 | Modulators of HSD17b7 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of hydroxysteroid (17-beta) dehydrogenase type 7, and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or in vitro prognosis of these pathologies are also described. | 02-04-2010 |
20100035988 | Methods for activating PPAR gamma-type receptors - Novel biaromatic compounds having the following structural formula (I): | 02-11-2010 |
20100057369 | Corrective methodology for processing results of transcriptome experiments obtained by differential analysis - A corrective method for processing results of transcriptome experiments obtained by differential analysis includes the following steps:
| 03-04-2010 |
20100099689 | METHODS OF MODULATING PPAR GAMMA-TYPE RECEPTORS - Novel compounds having the general formula (I) below: | 04-22-2010 |
20100168089 | UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE - An in vitro method of screening for candidate compounds for the preventive or curative treatment of acne entails determination of the ability of a compound to inhibit the expression or the activity of TACE, and also to the administration of inhibitors of the expression or of the activity of this enzyme, in the treatment of acne. | 07-01-2010 |
20100233718 | NON-INVASIVE TECHNIQUE FOR CONDUCTING SKIN INFLAMMATORY DISEASE PHARMACO-GENOMIC STUDIES AND DIAGNOSES THEREOF - Non-invasive techniques to conduct skin inflammatory disease pharmaco-genomic studies and diagnoses thereof feature discriminating biomarkers and genes and in vitro diagnostic methods employing such biomarkers. | 09-16-2010 |
20100247468 | Compounds that modulate PPAR gamma-type receptors and cosmetic/pharmaceutical compositions comprising said compounds - Novel compounds having the general formula (I) below: | 09-30-2010 |
20100247583 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel N-phenylacetamide compounds of formula (I): | 09-30-2010 |
20110229423 | PACAP SIGNALING PATHWAY MODULATORS FOR TREATING INFLAMMATORY SKIN DISEASES HAVING A NEUROGENIC COMPONENT, NOTABLY ROSACEA, AND COMPOSITIONS COMPRISED THEREOF - Modulators of specific PACAP receptors are useful for treating inflammatory skin diseases having a neurogenic component, and more particularly rosacea and/or facial erythema, compositions containing these and screening methods are described for identifying PACAP signaling pathway modulators. | 09-22-2011 |
20130005803 | USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS - The use of compounds in the treatment of skin disorders is described. In particular, the use of a compound of formula (I) | 01-03-2013 |
20130017969 | MARKERS AND METHOD FOR THE DIAGNOSIS OF ROSACEA - Markers for rosacea among the chemokines and cytokines and their receptors, selected from interleukin 8 (IL-8), CXCL1, CXCL2, CXCL3 and CXCL5, the CXCR1 receptor and the CXCR2 receptor are described. Also described, is a method for the diagnosis of rosacea. | 01-17-2013 |
20130231393 | USE OF SQUARAMIDE IN THE PREVENTION AND/OR TREATMENT OF ROSACEA - A compound of formula (I): | 09-05-2013 |
20140024725 | MODULATORS FOR TRPA1 FOR THE TREATMENT OF ROSACEA - An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRP) cation channel, subfamily A, member 1(TRPA1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology. | 01-23-2014 |
20140031341 | MODULATORS AND METHODS FOR THE TREATMENT OF ROSACEA - An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology. | 01-30-2014 |
20140243523 | HUMAN EPITHELIAL CELL LINE FOR 3-D MODELIZING OF CANCER AND TREATMENT THEREOF - A cellular model is described that targets dysregulation or inappropriate activation of the Sonic Hedgehog/Patched (SHH/PTCH) pathway. Also described, is a screening method using this cellular model to screen for pharmacological compounds that can treat or prevent skin cancer, in particular, Basal Cell Carcinoma (BCC) lesions. | 08-28-2014 |
20140275108 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS - Provided herein are novel benzenesulfonamide compounds having a structure of formula (I) below: | 09-18-2014 |
20140296254 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES - Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are described that correspond to general formula (I). Also described, are pharmaceutical compositions that include these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases. | 10-02-2014 |
20140309208 | DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED PATHOLOGIES - Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds are disclosed that are represented by general formula (I). Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated pathologies. | 10-16-2014 |
20150087675 | NOVEL DISUBSTITUTED 3,4-DIAMINO-3-CYCLOBUTENE-1,2-DIONE COMPOUNDS FOR USE IN THE TREATMENT OF CHEMOKINE-MEDIATED DISEASES - Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to general formula (I) are disclosed. Also disclosed, are pharmaceutical compositions including these compounds and methods of using these compounds and compositions for the treatment of chemokine-mediated diseases. | 03-26-2015 |